Patient‐reported outcomes of topical finasteride/minoxidil treatment for male androgenetic alopecia: A retrospective study using telemedical data
Journal of Cosmetic Dermatology · 2024
DOI: 10.1111/jocd.16360 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Cosmetic Dermatology, 2024. Verfasst von Finn Abeck und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Finasteride, Alopecia, Patient Reported Outcome Measures, Minoxidil. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Oral finasteride and topical minoxidil are the current standard of care for male androgenetic alopecia and a combination of the two treatments can be considered for greater efficacy. Clinical trials of topical finasteride have also yielded promising results, but routine care data are lacking.
Aims
To examine patient‐reported outcomes of men with androgenetic alopecia who received topical finasteride admixed with minoxidil compared to the current standard of care (oral finasteride).
Methods
Retrospective, cross‐sectional study with data from a German direct‐to‐consumer teledermatology platform between December 2021 and January 2023. Patient‐reported outcomes were collected through voluntary follow‐up questionnaires provided after 6 weeks on topical finasteride/minoxidil or oral finasteride treatment.
Results
A total of 1545 patients who received topical finasteride/minoxidil treatment were included; 238 (15.4%) participated in the follow‐up questionnaire. At week six, 62.2% (148/238) reported positive changes in their hair appearance, and 44.1% (105/238) reported an improvement of self‐esteem. Treatment‐related adverse events were reported in 11.8% (28/238). Full treatment adherence was observed in 74.4% (177/238). Comparing the topical treatment group to those receiving oral finasteride, lower treatment adherence was reported, along with higher rates of local adverse events; no difference was found in the incidence of sexual adverse events.
Conclusion
Based on patient‐reported outcomes, topical finasteride/minoxidil seems to be effective and well tolerated, but not superior to oral finasteride. Lower treatment adherence for topical usage must be considered when considering treatment options. Additional real‐world data are needed to further evaluate the efficacy and safety of topical finasteride/minoxidil.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Wellster Healthtech Group, Munich, Germany.
ORCID-Profile: Finn Abeck, Florian Schröder, Johannes von Büren
Zitieren
APA
Abeck, F., Hansen, I., Kött, J., Schröder, F., Garrahy, E., Veneroso, J., Rünger, A., Torster, L., Schneider, S. W., & von Büren, J. (2024). Patient‐reported outcomes of topical finasteride/minoxidil treatment for male androgenetic alopecia: A retrospective study using telemedical data. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16360
Vancouver
Abeck F, Hansen I, Kött J, Schröder F, Garrahy E, Veneroso J, et al. Patient‐reported outcomes of topical finasteride/minoxidil treatment for male androgenetic alopecia: A retrospective study using telemedical data. Journal of Cosmetic Dermatology. 2024. doi:10.1111/jocd.16360
BibTeX
@article{Abeck2024,
author = {Abeck, Finn and Hansen, Inga and Kött, Julian and Schröder, Florian and Garrahy, Edward and Veneroso, Juliana and Rünger, Alessandra and Torster, Leopold and Schneider, Stefan W and von Büren, Johannes},
title = {Patient‐reported outcomes of topical finasteride/minoxidil treatment for male androgenetic alopecia: A retrospective study using telemedical data},
journal = {Journal of Cosmetic Dermatology},
year = {2024},
doi = {10.1111/jocd.16360}
}
EUVIMED